Soluble N-cadherin fragment promotes angiogenesis by Derycke, Lara et al.
Abstract Endothelial cells express two dependent
intercellular adhesion molecules: vascular endothelial
(VE)-cadherin, specific for endothelial cells, and N-
cadherin, also present in neuronal, lens, skeletal and
heart muscle cells, osteoblasts, pericytes and fibro-
blasts. While there exists a vast amount of evidence
that VE-cadherin promotes angiogenesis, the role of
N-cadherin still remains to be elucidated. We found
that a soluble 90-kDa fragment N-cadherin promotes
angiogenesis in the rabbit cornea assay and in the
chorioallantoic assay when cleaved enzymatically from
the extracellular domain of N-cadherin. Soluble
N-cadherin stimulates migration of endothelial cells in
the wound healing assay and stimulates phosphoryla-
tion of extracellular regulated kinase. In vitro experi-
ments with PD173074 and knock-down of N-cadherin
and fibroblast growth factor (FGF)-receptor, showed
that the pro-angiogenic effect of soluble N-cadherin is
N-cadherin- and FGF-receptor-dependent. Our results
suggest that soluble N-cadherin stimulates migration of
endothelial cells through the FGF-receptor.
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Introduction
Angiogenesis is the process of endothelial cells
detaching from the vascular wall, invading the under-
lying tissues, and forming tubes that branch and orga-
nise into anastomotic networks [1]. Angiogenesis
occurs in physiological (embryology, ovulation, wound
healing) and in pathological situations (neoplasia, dia-
betic retinopathy, rheumatoid arthritis) [2]. The process
is regulated by a balance between pro- and anti-angio-
genic molecules, emanating from endothelial, stromal
and epithelial cells [3], by comprising growth factors [4],
proteinases [5] and their respective inhibitors [6],
extracellular matrix molecules [7], and also by cell–cell
and cell–substratum adhesion molecules [8].
In vivo angiogenesis in cornea or chorioallantoic
membrane (CAM) models, induced by fibroblast
growth factor (FGF)-2 depends on avb3 integrin,
whereas angiogenesis induced by vascular endothelial
growth factor type A (VEGF-A) depends on avb5
integrin. Antibody to avb3 and avb5 receptor for vitro-
nectin blocked angiogenesis in the chick CAM induced
by FGF-2 and VEGF-A, respectively [9–11]. Vitro-
nectin not only binds to integrins, but also to urokinase
plasminogen activator receptor (uPAR) [12], both
localised at focal adhesion sites. uPAR can stimulate
endothelial migration in two ways: first by plasmin
formation and subsequent proteolytic degradation of
the extracellular matrix [13], and second, by direct
interaction with vitronectin. Vascular endothelial
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(VE)-cadherin, a cell–cell adhesion molecule specific
for endothelial cells serves interendothelial cell–cell
adhesion and prevents endothelial apoptosis [2]. Neural
(N)-cadherin is a cell adhesion molecule expressed by
various cells, like neurons, fibroblasts, oocytes, sperm-
atides, Sertoli cells, lens cells, osteoblasts and also by
endothelial cells. Homophilic homotypic N-cadherin
interaction in non-endothelial cells, like in cardiomyo-
cytes serves stabilisation of the adherens junction [14].
Heterotypic N-cadherin interactions on the other hand
stimulate migration. Various cancer cells invade the
surrounding stroma by expressing N-cadherin aber-
rantly [15], and neural cells migrate on oligodendro-
cytes, expressing N-cadherin as well [16]. The function
of N-cadherin in angiogenesis remains to be elucidated.
Homophilic heterotypic interactions exists between
endothelial and stromal cells [17], specifically between
endothelial cells and pericytes [18, 19]. Also homotypic
N-cadherin interactions were found at the intercellular
junctions in endothelial cells. Luo and Radice [20]
concluded that N-cadherin controls vasculogenesis up-
stream of VE-cadherin, because loss of N-cadherin in
endothelial cells results in embryonic lethality at mid-
gestation due to severe vascular defects. The knock-
down of N-cadherin caused a significant decrease in
VE-cadherin expression.
Our laboratory has provided evidence that an 80-
kDa epithelial (E)-cadherin fragment (sE-CAD), re-
leased by plasmin, matrilysin or stromelysin-1, affects
epithelial tissue integrity, causing loss of cell–cell
adhesion and gain of invasion [21, 22]. Similar soluble
fragments are released from cells expressing N-cadh-
erin (sN-CAD), and they also exert regulatory func-
tions, such as during neurite outgrowth in the retina of
the chick embryo [23]. The aim of the present study
was to identify a possible effect of sN-CAD on angio-
genesis. We found that sN-CAD mediated the invasion
of endothelial cells into the extracellular matrix during
angiogenesis, like sE-CAD mediated the invasion of
cancer cells. Therefore, we used N-cadherin expressing
mouse sarcoma cells as a source of sN-CAD. We found
that sN-CAD stimulated angiogenesis in vivo. In vitro
studies revealed that sN-CAD is able to stimulate
migration of endothelial cells through activation of the
FGF-receptor.
Materials and methods
Cell lines
Human endothelial cells, PSV1, derived from umbilical
veins (a gift from Ve´ronique Fafeur, Institut Pasteur de
Lille) [24]. These cells were checked after thawing for
endothelial cell markers VE-cadherin, N-cadherin and
factor VIII. All experiments were done with cells be-
tween passage 3 and 10. Cells were grown on 0.1%
gelatin-coated dishes in RPMI 1640 (Invitrogen,
Merelbeke, Belgium) supplemented with 20% fetal
bovine serum, 100 IU/ml penicillin (Invitrogen),
100 lg/ml streptomycin (Invitrogen) and 2.5 lg/ml
Fungizone (Bristol-Meyers Squibb, Brussels, Bel-
gium). S180-NCAD and S180 cells, mouse sarcoma
cells (a gift from R.M. Me`ge, INSERM, Paris, France)
[25] were grown in DMEM (Invitrogen, Merelbeke,
Belgium) supplemented with 10% fetal bovine serum
and penicillin, streptomycin and Fungizone (see
above). The S180-NCAD cells, used as a source of sN-
CAD, are S180 cells transfected with chicken cDNA
encoding for N-cadherin. The cells were incubated in
an 100% water-saturated atmosphere of 5% CO2 for
PSV1 and 10% CO2 for S180-NCAD and S180 cells.
All cells were routinely tested for mycoplasma con-
tamination by staining with 4¢,6-diamidino-2-pheny-
lindole (DAPI) and found negative.
Reagents and antibodies
A 10-mer histidine–alanine–valine (HAV)-comprising
peptide, identical to amino acids 235–244 in the first
extracellular domain of N-cadherin (hu N-CAD10,
LRAHAVDING) [26] served as a peptidomimetic for
the first extracellular domain (ECD1) of N-cadherin.
As a control, a scrambled 10-mer peptide (scrambled
N-CAD10, LHDANVGRIA) (Eurogentec, Seraing,
Belgium) was included. Recombinant human N-cadh-
erin/Fc chimera was purchased from R&D Systems
(Abingdon, UK). Recombinant human basic fibroblast
growth factor (FGF-2) (Sigma, St Louis, MO, USA)
and recombinant human vascular edothelial growth
factor (VEGF-A) (R&D Systems, Abingdon, UK)
were used as positive control. Cortisone acetate (Sig-
ma, St Louis, MO, USA) was used to block the process
of inflammation in the chorioallantoic assay.
PD173074, a selective inhibitor of the FGF-receptor
[27] was a gift from P. Doherty (King’s College Lon-
don, UK).
The antibodies used for immunoprecipitation were
rabbit polyclonal anti-human b-catenin (Sigma, St
Louis, MO, USA), rabbit polyclonal anti-human
FGF-receptor (FGFR1) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), mouse monoclonal anti-pan
cadherin (CH-19) (Sigma, St Louis, MO, USA) and
mouse IgG isotype control (eBiosciences). The rat
monoclonal antibody NCD-2 (a gift from C. Redies,
University Hospital Essen, Germany) [28] was used for
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immunodepletion of sN-CAD out of the medium
containing sN-CAD. The primary antibodies for Wes-
tern blot were: mouse monoclonal antibody GC-4, CH-
19 (Sigma, St Louis, MO, USA) and 13A9 (kindly
provided by M.J. Wheelock, Department of Biology,
University of Toledo, Toledo, OH, USA) against N-
cadherin, mouse monoclonal antibody anti-a-tubulin
(Sigma, St Louis, MO, USA), rabbit polyclonal anti-
body anti-phospho-ERK kinase and rabbit polyclonal
antibody anti-ERK kinase (Cell Signaling technology,
Beverly, MA, USA). The secondary antibodies were
anti-mouse or anti-rabbit antibody linked to horse-
radish peroxidase (Amersham Pharmacia Biotech).
Electroporation
PSV1 cells were seeded and, at 70–80% confluency,
were trypsinised and collected in a NucleofectorTM
certified cuvette (Amaxa GmBH, Cologne, Germany).
A mixture of 100 ll Nucleofector solution and 3 lg of
short interference RNA (siRNA) was added. The cells
were electroporated in the Nucleofector electroporator
with the A34-specific Nucleofector program. siRNAs
targeting N-cadherin (GenBank/EMBL/DDBJ acces-
sion number NM-001792) were designed by Qiagen
(Leusden, The Netherlands). Inhibition of N-cadherin
expression was achieved by RNA interference using
the following double-stranded oligoribonucleotides:
siN-cad2 5¢-AGUGGCAAGUGGCAGUAAA-3¢
and siN-cad3 5¢-GGAGUCAGCAGAAGUUGAA-3¢
[29]. siRNA targeting FGFR1 (GenBank/EMBL/
DDBJ accession number NM-000604) were designed
by DHARMACOM (Lafayette, CO, USA). The
FGFR1 siRNA represented mixtures of four distinct
RNA duplexes (SmartPool). To verify specificity of
the knock-down effect, we used an oligonucleotide
sequence with no known mammalian target (con
5¢-UUCUCCGAACGUGUCACGU) as a control.
Preparation of medium containing sN-CAD
Confluent monolayers were washed three times with
phosphate buffered saline (PBS) and incubated for 2 h
at 37C with serum-free DMEM to which plasmin 1 lg/
ml (Sigma, St Louis, MO, USA) was added. Our re-
combinant N-cadherin could also be cleaved by plas-
min and releasing a 90-kDa fragment. sN-CAD was
also spontaneously released by the cells: for this sub-
confluent monolayers were washed three times with
PBS and put on serum-free medium (SFM) for 24 h,
washed another three times with PBS and incubated
for 48 h with Serum-free medium. The medium con-
taining sN-CAD was harvested, centrifuged at 250g for
5 min followed by a centrifugation step at 2,000g for
15 min and filtered through a 0.22 lm filter. The
medium containing sN-cad after plasmin treatment or
the medium after 48 h contact with the cells was always
checked by western blot for the presence of the 90-kDa
N-cadherin fragment before use in functional assays
(see also Fig. 2). sN-CAD was removed from the
medium by immunoadsorption as follows. Medium
containing sN-CAD was incubated four times for 1 h
with protein G-Sepharose 4 fast flow beads (Amer-
sham Pharmacia Biotech) coated with NCD-2 antibody
against N-cadherin. Beads and supernatants were sep-
arated and the remaining supernatant was finally fil-
tered through a 0.22 lm filter. Medium without sN-
CAD (serum-free DMEM) was also incubated for 2 h
at 37C with 1 lg/ml plasmin for evaluation of the ef-
fect of plasmin on angiogenesis. Media with or without
sN-CAD were concentrated twice (Amicon Ultra
50 kDa, Millipore Corp., Bedford, MA, USA) before
use in angiogenesis assays in vivo and in vitro assays.
Rabbit cornea assay
In vivo angiogenesis was studied in the cornea of New
Zealand rabbits (Charles River, Calco, Como, Italy)
since this is an avascular and transparent tissue, where
inflammatory reactions and growing capillaries can be
easily monitored and changes quantitated by stereo-
microscopic examination. Slow-release pellets were
prepared under sterile conditions, incorporating the
test substances into a casting solution of an ethynil-
vinyl copolymer (Elvax-40, DuPont-De Nemours,
Wilmington, DE, USA). Rabbits were anaesthetised
by sodium pentothal (30 mg/kg) and in the lower half
of the eyes, one or two micropockets were surgically
made using an iris spatula. The pellets were implanted
in the micropockets. Pellets impregnated with re-
combinant growth factor FGF-2 (R and D Systems,
Abingdon, UK) were used as positive control [30].
Subsequent daily observations of the implants were
made with a slit lamp stereomicroscope by two inde-
pendent operators. Angiogenic activity is indicated by
the number of implants exhibiting neovascularisation
over the total implants studied, and by the angiogenic
score. The angiogenic score was considered positive
when budding of vessels from the limbal plexus oc-
curred after 3–4 days and capillaries progressed to
reach the implanted pellet. The angiogenic score is
calculated by the number of newly formed vessels and
by their growth rate (number of vessels · distance
from the limbus) [31]. A density value of 1 corre-
sponded to 0–25 vessels per cornea, 2 from 25–50, 3
from 50–75, 4 from 75–100 and 5 for > 100 vessels.
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The distance from the limbus was graded with the aid
of an ocular grid. The Student’s t-test for unpaired data
was used for statistics (p < 0.05).
CAM assay
The CAM assay was performed as described by Ma-
ragoudakis et al. [32] with some modifications. Briefly,
fertilised eggs were incubated for 3 days at 37C. On
day 3, albumen was removed to detach the shell from
the developing CAM. On day 4, a window was made in
the eggshell, exposing the CAM, and covered with
cellophane tape. The eggs were returned to the incu-
bator until day 9, prior to application of the test com-
pounds. Test compounds and control compound (PBS)
were poured onto separate sterile discs (11 mm diam-
eter), which were allowed to dry under sterile condi-
tions. A solution of cortisone acetate (100 lg/disc) was
poured onto all discs to prevent an inflammatory re-
sponse. Test discs probed with the 165 amino acid
isoform of VEGF-A served as positive control. On
each CAM, the disc containing control compound and
the disc containing test compound were placed at a
distance of 1 cm. The windows were covered and the
eggs were incubated until day 11, before assessment of
angiogenesis. Therefore, the eggs were flooded with
10% buffered formalin, the discs were removed, and
the eggs were kept at room temperature for at least
2 h. A large area around the discs was cut out and
placed on a glass slide, and the vascular density index
was measured by the method of Harris-Hooker et al.
[33]. Briefly, a grid containing three concentric circles
of 6-, 8- and 10-mm diameter was positioned on the
surface of the CAM previously covered by the disc. All
vessels intersecting the circles were counted. The
angiogenic index = (t–c)/c, with t the number of inter-
sections in the area covered by the test disc and c the
number of intersections in the area covered by the
control disc in the same egg. All experiments were
performed at least twice, and the Mann–Whitney U-
test was used for statistics (p < 0.05).
Wound healing migration assay
Cells were grown in 6-well tissue culture dishes until
confluent. Medium was removed and the monolayers
were wounded with a plastic tip. Wounded monolayers
were washed three times with Ca2+- and Mg2+-con-
taining PBS pH 7.4 to remove dead cells. Cell migra-
tion occurred in 1 ml serum-free medium. Wounds
were marked and measured at time points zero and
16 h with an inverted microscope. The migration dis-
tance of the untreated cells was put at 100% and
compared to the treated cultures. The Student’s t-test
was used for statistics (p < 0.05).
F-actin staining
Cells were grown on glass coverslips in 24-well culture
dishes until islands of cells were formed. Cells were
washed with PBS and serum-starved overnight, followed
by treatment or left untreated for 6 h in serum-free
medium. Cells were fixed in 3% paraformaldehyde,
blocked in 50 mM NH4Cl in PBS, permeabilised in 0.2%
Triton-X-100 in PBS and stained with phalloidin-FITC
(Sigma, St Louis, MO, USA).
Immunoprecipitation and Western blotting
All cell lysates were made from cell cultures at approxi-
mately 70% confluence. All cells were washed three
times with PBS, serum-starved over-night, washed again
three times and treated for the indicated times. Cells
were lysed with PBS containing 1% Triton X-100 and
1% Nonidet P-40 and the following protease- and
phosphatase inhibitors: aprotinin (10 lg/ml), leupeptin
(10 lg/ml), phenylmethylsulphonyl fluoride (1.72 mM),
NaF (10 mM), NaVO3 (1 mM) and Na4P2O7 (1 mM)
(Sigma, St Louis, MO, USA). For the co-immunopre-
cipitation of FGF-receptor and N-cadherin the follow-
ing lysis buffer was used: 50 mM Tris–HCl pH of 7.5,
150 mM NaCl, 1% Nonidet P-40 and the same protease-
and phosphatase inhibitors as described above. The
protein concentration was measured using Rc Dc pro-
tein assay (Bio-Rad), and samples were prepared at
equal protein concentrations. For immunoprecipitation,
equal amounts of proteins were first incubated with
protein A or G-Sepharose beads (Amersham Pharmacia
Biotech) for 30 min. After discarding the beads, the
supernatant was incubated with primary antibody for
3 h at 4 C, followed by incubation with protein A or
G-Sepharose beads for 1 h. Sample buffer (Laemmli)
with 5% 2-mercaptoethanol and 0.012% bromophe-
nolblue was added, followed by boiling for 5 min
and separated on 8% SDS-PAGE and transferred on a
nitrocellulose membrane (Amersham Pharmacia
Biotech). Quenching and immunostaining were done in
5% non-fat dry milk in PBS containing 0.5% Tween 20,
except for anti-phospho-ERK antibody, where 4%
bovine serum albumin in PBS containing 0.2% Tween 20
was used instead. The membranes were quenched for
1 h, incubated with primary antibody for 1 h, washed
four times for 10 min, incubated with horseradish
peroxidase-conjugated secondary antibody for 45 min,
and washed six times for 10 min. Detection was carried
out using enhanced chemiluminescence reagent
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(Amersham Pharmacia Biotech) as a substrate. To
control for equal loading of total lysates, immunostain-
ing with anti-tubulin antibody was performed. Quanti-
fication of the bands was done using Quantity-One
software (Bio-Rad).
Results
HAV-comprising N-CAD10 peptide promotes
angiogenesis in vivo
The effect of hu N-CAD10 peptide, comprising the
HAV motif of the first extracellular domain of N-
cadherin, was examined in the CAM (chorioallantoic
assay) (Fig. 1a). VEGF-A (1 lg/ml), Serum-free med-
ium without and with hu N-CAD10 peptide (2 lg/ll) or
with scrambled peptide (2 lg/ll) were tested. VEGF-A
and hu N-CAD10 peptide induced angiogenesis, 45 and
27.7%, respectively, with angiogenic indices that were
statistically different from the angiogenic index of the
scrambled peptide. Serum-free medium with or with-
out scrambled peptide did not induce angiogenesis.
Different concentrations of hu N-CAD10 peptide
and scrambled peptide were tested in the rabbit cornea
assay (Fig. 1b). Mean angiogenic scores of hu N-
CAD10 peptide were concentration-dependent. Low
doses of hu N-CAD10 peptide (200 and 500 ng/pellet)
were devoid of any angiogenic capacity (0/4 rabbit
corneas were positive for both concentrations). Pellets
impregnated with 10 or with 50 lg hu N-CAD10 pep-
tide induced angiogenesis in, respectively, 2/3 and 3/3
rabbit corneas. Pellets impregnated with 10 or 50 lg
scrambled N-CAD10 peptide induced angiogenesis in
only 1 rabbit cornea (1/3 rabbit corneas positive for
both concentrations). The mean angiogenic score of
rabbit corneas probed with pellets impregnated with
hu N-CAD10 peptide in any concentrations was
statistically different from the angiogenic score of
rabbit corneas probed with pellets impregnated with
Fig. 1 hu N-CAD10 peptide induces angiogenesis. a hu N-
CAD10 peptide induces angiogenesis in the CAM. Bars indicate
angiogenic indices of CAM probed with VEGF-A (1 lg/ml),
serum-free medium without or with hu N-CAD10 peptide 2 lg/
ll, or with a scrambled N-CAD10 peptide 2 lg/ll. Each value
(mean + standard deviation) is the result of three experiments.
In each experiment, five eggs were tested per condition.
*Statistically different from the mean angiogenic index of
CAMs probed with scrambled peptide (Mann–Whitney U-test,
p < 0.05). b hu N-CAD10 peptide induces angiogenesis in the
rabbit cornea. Angiogenic scores of rabbit corneas probed with
pellets impregnated with hu N-CAD10 peptide 200 ng (closed
diamonds, n = 4), hu N-CAD10 peptide 500 ng (closed squares,
n = 4), hu N-CAD10 peptide 10 lg (closed triangles, n = 3), hu
N-CAD10 peptide 50 lg (closed circles, n = 3), scrambled N-
CAD10 peptide 10 lg (open triangles, n = 3) and scrambled N-
CAD10 peptide 50 lg (open circles, n = 3). Symbols represent
the mean + standard deviation of angiogenic scores of n number
of rabbit corneas tested. *Statistically different from the mean
angiogenic score of rabbit corneas probed with scrambled
peptide 10 lg (Student’s t-test, p < 0.05)
c
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scrambled peptide. No inflammatory effect was
microscopically observed at any of the concentrations
tested.
In these in vivo experiments we could prove that the
HAV-comprising N-cadherin peptide induced angio-
genesis.
sN-CAD promotes angiogenesis in vivo
To approach the physiological situation, we used for all
further experiments soluble N-cadherin, which is re-
leased from the mature N-cadherin after enzymatical
cleavage. Different enzymes, like matrix metallopro-
teinases (MMP), plasmin, ADAM10, are able to shed
the 90-kDa N-cadherin fragment. sN-CAD is also
present in different body fluids of the patients, like the
serum [34].
Medium from S180-NCAD cells treated with 1 lg/
ml of plasmin was collected after 2 h (MsN pl). This
medium was used in the CAM assay because we pre-
sumed it contained less growth factors than the 48 h
medium containing sN-CAD. Medium harvested
from S180-NCAD cells after a 48 h incubation-period
with Serum-free medium contained spontaneously re-
leased sN-CAD (MsN) (Fig. 2a). The immunosignal
for sN-CAD was present at 90 kDa in medium con-
taining sN-CAD, but not when sN-CAD was immun-
Fig. 2 Detection of sN-CAD and induction of angiogenesis.
a Immunodepletion of medium containing sN-CAD is performed
by immunoadsorption with NCD-2 antibody-coated beads
removing sN-CAD. Lanes represent medium containing sN-
CAD, immunodepleted medium and sN-CAD linked to NCD-2
antibody-coated beads used for immunodepletion of medium
containing sN-CAD. As a control for sN-CAD containing
medium, spontaneously released sN-CAD was used. For this
purpose, S180-NCAD cells were incubated with serum-free
medium (Serum-free medium) and medium was harvested after
48 h. As control for the sN-CAD depletion we used an isotype
control antibody. Media and beads were separately dissolved in
sample buffer, and proteins were separated by SDS-PAGE,
blotted and immunostained with NCD-2 antibody. b Bars
indicate angiogenic indices of CAMs probed with VEGF-A
1 lg/ml, Serum-free medium, Serum-free medium with plasmin
1 lg/ml, medium containing sN-CAD or sN-CAD immunode-
pleted medium. Each value (mean + standard deviation) is the
result of three experiments. In each experiment, five eggs were
tested per condition. *Statistically different from the mean
angiogenic index of CAMs probed with serum-free medium
(Mann–Whitney U-test, p < 0.05). c Angiogenic scores of rabbit
corneas, probed with pellets impregnated with Serum-free
medium (diamonds, n = 4), Serum-free medium with plasmin
(triangles, n = 5), medium containing sN-CAD (squares, n = 6),
or sN-CAD immunodepleted medium (circles, n = 3). Symbols
represent the mean of angiogenic scores of n number of rabbit
corneas tested. Flags represent standard deviations. *Statistically
different from the mean angiogenic score of rabbit corneas
probed with pellets impregnated with Serum-free medium
(Student’s t-test, p < 0.05)
c
192 Clin Exp Metastasis (2006) 23:187–201
123
odepleted by immunoadsorption. NCD-2 antibody-
treated beads, used for immunoadsorption of sN-CAD,
also showed an immunosignal for sN-CAD. When the
medium containing sN-CAD was immunodepleted
with an isotype control antibody, there was no change
in MsN and no immunosignal appeared in isotype
antibody-treated beads.
The effect of sN-CAD on angiogenesis was exam-
ined in the CAM assay (Fig. 2b). VEGF-A, Serum-free
medium, plasmin, medium containing sN-CAD and
sN-CAD immunodepleted medium were tested. Only
VEGF-A and medium containing sN-CAD induced
angiogenesis statistically different from Serum-free
medium (p < 0.05). Results with plasmin alone were
not statistically different from those with Serum-free
medium. sN-CAD immunodepleted medium did not
induce angiogenesis compared to Serum-free medium
while sN-CAD medium depleted with isotype control
antibody gave the same angiogenesis response as the
non-depleted medium.
Medium containing sN-CAD, sN-CAD immun-
odepleted medium and Serum-free medium with and
without plasmin were also tested in the rabbit cornea
assay (Fig. 2c). The mean angiogenic score of rabbit
corneas probed with pellets impregnated with med-
ium containing sN-CAD, was 7 and statistically dif-
ferent from the mean angiogenic score of rabbit
corneas probed with pellets impregnated with Serum-
free medium. Six out of six rabbit corneas probed
with pellets impregnated with medium containing sN-
CAD were positive. Pellets impregnated with sN-
CAD immunodepleted medium or with Serum-free
medium with plasmin induced angiogenesis in,
respectively, 1/3 and 1/5 rabbit corneas. The mean
angiogenic score of rabbit corneas probed with pellets
impregnated with sN-CAD immunodepleted medium
or with Serum-free medium with plasmin did not
differ statistically from the mean angiogenic score of
rabbit corneas probed with pellets impregnated with
Serum-free medium. sN-CAD induced angiogenesis
the CAM and in the rabbit cornea assay.
sN-CAD-stimulated migration in vitro is
N-cadherin-dependent
Since angiogenesis is dependent on migration of
endothelial cells we were interested whether sN-CAD
modulates the migration of endothelial cells in the
wound healing migration assay in vitro. Confluent
PSV1 cultures were serum-starved for a minimum of
24 h to establish quiescence such that the presence of
cells in the wounded area was owed to cell motility
rather than cell proliferation. After wounding the
monolayer, PSV1 cells were treated with different
concentrations (0.5–2 mg/ml) of the hu N-CAD10 pep-
tide (Fig. 3a). Endothelial cells migrated perpendicu-
larly to the wound in a irregular shaped front and there
was a statistically difference in migration between hu
N-CAD10 peptide treated cells (144%) and serum-free
treated cells (100%). Next, we treated wounded PSV1
monolayers with Serum-free medium containing sN-
CAD (MsN) or with Serum-free medium (Fig. 3b).
Medium containing sN-CAD induced migration that
was significantly faster (228%) than cells treated with
Serum-free medium (100%). Medium from S180, not
expressing N-cadherin, was also tested in the wound
healing assay but had no stimulatory effect on the
PSV1, S180-NCAD or S180 cells. Moreover, re-
combinant N-cadherin (RECN), which consist of the
extracellular domain of N-cadherin linked to the Fc
fragment of human IgG1, stimulated migration of PSV1
cells in a dose response manner (0–10 lg/ml) (Fig. 3c).
Untreated PSV1 cells migrated slower compared to
PSV1 cells treated with 10 lg/ml of RECN (100%
versus 201%). Other recombinant cadherins like E- or
P-cadherin did not stimulate the migration of the
endothelial cells. For all migration assays, knock-down
and immunocytochemistry experiments we used RECN
at a concentration of 5 lg/ml. Furthermore, we use this
in vitro assay to analyse the molecular mechanism of
sN-CAD-stimulated migration.
We found the presence of full-length N-cadherin to
be a prerequisite for the stimulatory effect of sN-CAD.
Migration of S180-NCAD cells, transfected with full-
length N-cadherin and their parental S180 cells devoid
of N-cadherin, were compared (Fig. 3b). S180-NCAD
cells treated with their own medium containing sN-
CAD (MsN) migrated significantly faster then S180-
NCAD cells treated with Serum-free medium (144 and
100%, respectively). Migration of S180 cells (100%)
was not stimulated by adding MsN (95%).
To confirm the role of N-cadherin in sN-
CAD-stimulated migration, we used the siRNA
knock-down approach. N-cadherin expression was
silenced using siRNA. For this, endothelial cells were
electroporated with two double-stranded oligonucleo-
tides derived from different regions of N-cadherin
cDNA. PSV1 cells electroporated either with control
oligonucleotide or without were used as controls. As
revealed by Western blot analysis 72 h after transfec-
tion, siN-cadherin suppresses N-cadherin protein
expression by 93% (see Fig. 5). After 48 h, confluent
monolayers of electroporated PSV1 cells were woun-
ded and treated with or without RECN (5 lg/ml)
(Fig. 3d). Control cells were stimulated by RECN
(5 lg/ml) in the wound healing assay (not: Serum-free
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medium 100% and RECN 119% and scramble: Serum-
free medium 104% and RECN 127%). RECN-stimu-
lated migration of N-cadherin silenced cells was ham-
pered in comparison with not or control transfected
cells (siNCAD2 Serum-free medium 92% and RECN
95% and siNCAD3 Serum-free medium 113% and
RECN 103%).
The pro migratory effect of sN-cad on PSV1 cells in
the wound healing assay was dependent on N-cadherin.
sN-CAD-stimulated migration in vitro is
FGF-receptor-dependent
We investigated a possible association between full-
length N-cadherin and the FGF-receptor (Fig. 4a).
S180-NCAD cells of approximately 70% confluency
were lysed and co-immunoprecipitation was performed
using an antibody against the C-terminus of N-cadherin
or the C-terminus of the FGF-receptor. After gel elec-
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trophoresis, proteins were blotted and immunostained
using an antibody against N-cadherin and the FGF-
receptor. N-cadherin co-immunoprecipitated with the
FGF-receptor suggesting a direct or indirect interaction
between both molecules (as has been demonstrated
before in cell lines by Suyama et al. [35]).
We then examined the effect of sN-CAD on the
N-cadherin/FGF-receptor complex. S180-NCAD cells
were used at 70% confluency, followed by serum
starvation overnight. Cells were treated for 30 min
with Serum-free medium, medium containing sN-CAD
(MsN) or RECN. Cells were lysed and co-immuno-
precipitation was performed. In Serum-free medium-
treated cells N-cadherin still interacted with the FGF-
receptor. In sN-CAD-treated cells however, N-cadh-
erin was dissociated from the FGF-receptor (MsN 71%
and RECN 50%) (Fig. 4b).
We then examined the effect of PD173074, a specific
FGF-receptor inhibitor [27], on the migration of PSV1
and S180N-CAD cells. Wounded monolayers were
stimulated to migrate by treatment with RECN or FGF-
2 (12.5 ng/ml + heparin 5 lg/ml) (Fig. 4c). PSV1 and
S180-N-CAD cells that were treated with Serum-free
medium migrated slower then treatment with RECN
stimulated migration up to 134 and 127%. Addition of
500 nM PD173074 to RECN-treated cultures counter-
acted the pro-migratory effect of sN-CAD both in PSV1
and in S180-NCAD cells. By contrast, PD173074 alone
had no effect on migration of cells.
Next, the FGF-receptor was knocked down in PSV1
cells using siRNA. For this, endothelial cells were
electroporated with a pool of four double-stranded
oligonucleotides derived from different regions of
FGF-receptor cDNA. PSV1 cells electroporated either
with control oligonucleotide or without were used as
controls. As revealed by Western blot analysis 72 h
after transfection, siFGF-receptor suppresses FGF-
receptor protein expression by 74% (Fig. 5b). After
48 h, confluent monolayers of electroporated PSV1
cells were wounded and treated with or without RECN
(5 lg/ml) (Fig. 3d). Control cells were stimulated by
RECN (5 lg/ml) in the wound-healing assay (not:
Serum-free medium 100% and RECN 199% and
scramble: Serum-free medium 104 and 127%). RECN-
stimulated migration of FGF-receptor silenced cells
was hampered in comparison with control (siFGFR
Serum-free medium 76% and RECN 83%). We con-
clude that FGF-receptor expression and activity is
necessary to observe the pro-migratory effect of sN-
CAD in the wound-healing assay.
sN-CAD phosphorylates ERK
The FGF-receptor signals through the ERK pathway
to stimulate migration [11]. We therefore examined the
possible contribution of ERK as signalling component
in sN-CAD-stimulated migration of endothelial cells.
As shown in Fig. 5a, PSV1 and S180-NCAD cells were
grown until 70% confluency, followed by serum star-
vation overnight. Cells were treated for 30 min with
Serum-free medium, medium containing sN-CAD
(MsN), RECN (5 lg/ml) or FGF-2 (12.5 ng/ml), as a
positive control, in the presence or absence of
PD173074. ERK was hardly phosphorylated when
cultures were treated with Serum-free medium, but
ERK was strongly phosphorylated in PSV1 and S180-
NCAD cell lines treated with MsN, RECN or FGF-2
(Fig. 5a). Staining with the anti-ERK1/2 antibody and
anti-tubulin was used as control and remained the
same in all conditions. The relative intensity was cal-
culated by measuring the intensity of the p-ERK bands
compared to intensity of the total ERK bands.
PSV1 cells were knocked down for N-cadherin and
FGFR, using oligonucleotides, and were serum-starved
after 60 h and treated for 30 min in absence or pres-
ence of RECN. As revealed by Western blot analysis,
siRNA efficiently reduced N-cadherin and FGF-
receptor expression (Fig. 5b). Tubulin expression was
used as control for equal protein loading. Again,
phosphorylation of ERK was checked (Fig. 5b). By
knocking down the expression of N-cadherin and
FGF-receptor phosphorylation of ERK was strongly
Fig. 3 sN-CAD stimulates migration. a Confluent monolayers of
S180-NCAD (white bars) and PSV1 (grey bars) cells were
wounded with a plastic tip, and treated with hu NCAD10 peptide
in a concentration range of 0.5–2 mg/ml or with serum-free
medium (SFM). The distance of migration of Serum-free
medium-treated cultures was set at 100%. Each value
(mean + standard deviation) is the result of two experiments.
*Statistically different from the mean relative distance of Serum-
free medium-treated cultures (Student’s t-test, p < 0.05). b Con-
fluent monolayers of S180 (dotted bars), S180-NCAD (white bars)
and PSV1 (grey bars) cells were wounded with a plastic tip, and
treated with medium containing sN-CAD (MsN) or Serum-free
medium. Each value (mean + standard deviation) is the result of
three experiments. *Statistically different from the mean relative
distance of Serum-free medium-treated cultures (Student’s t-test,
p < 0.05). c Confluent monolayers of PSV1 cells were wounded
with a plastic tip, and treated with different concentrations of
recombinant N-cadherin (RECN, 1–10 lg/ml). Wounds were
marked and measured at time points zero and after 16 h. Bars
represent mean values of at least three independent experiments
and flags indicate standard deviation. *Statistically different from
the mean migration of Serum-free medium-treated cultures
(Student’s t-test, p < 0.05). d Confluent monolayers of siRNA-
transfected PSV1 cells were wounded after 48 h with a plastic tip
and subsequently treated with Serum-free medium (white bars) or
RECN (5 lg/ml) (grey bars). Wounds were marked and scored at
time zero and after 16 h. Bars represent mean value of one
experiment performed in triplet
b
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diminished in RECN-treated cell cultures. As control
these cells were also treated with FGF-2, in the FGF-
receptor silenced cells ERK could not be phosphory-
lated (data not shown).
Our experiments suggest that sN-CAD-stimulated
ERK activation is dependent on expression of N-
cadherin and FGF-receptor, and FGF-receptor activity.
sN-CAD induces cytoskeleton reorganisation
PSV1 and S180-NCAD were seeded at low density on
glass coverslips. Cells were put on Serum-free medium
and cells were treated further with Serum-free med-
ium, or with medium containing sN-CAD (MsN),
RECN, RECN with PD173074 or PD173074 alone for
Fig. 4 sN-cad activates the FGF-receptor. a Subconfluent mono-
layers of S180-NCAD were solubilised in low detergent lysis
buffer and immunoprecipitation was performed with an antibody
against N-cadherin or the FGF-receptor. The precipitated
proteins were resolved by SDS-PAGE, and immunoblots were
stained with antibody against N-cadherin. b sN-CAD dissociates
the N-cadherin/FGF-receptor interaction. Serum starved S180-
NCAD cells were treated 30 min with serum-free medium
(SFM) (without sN-CAD), medium containing sN-CAD (MsN)
or RECN (5 lg/ml), followed by solubilisation in low detergent
lysis buffer. Equal amounts of protein were immunoprecipitated
with an antibody against the FGF-receptor, the precipitated
proteins were resolved by SDS-PAGE. Immunoblots were
stained for N-cadherin. The bands in the immunoblot stained
with anti-FGFR remained the same. All imunoblots were
quantified with the Quantity-One software and the relative
intensity of the N-cadherin/FGFR bands are showed in the figure
and this figure is representative for at least three independent
experiments performed. c Confluent monolayers of S180-NCAD
(white bars) and PSV1 (grey bars) cells were wounded with a
plastic tip and subsequently treated with Serum-free medium,
PD173074 (PD, 500 nM), RECN (5 lg/ml), RECN with PD,
FGF-2 (12.5 ng/ml) or FGF-2 with PD. Wounds were marked
and measured at time points zero and after 16 h. Bars represent
mean values of at least three independent experiments and flags
indicate standard deviation. *Statistically different from the
mean migration of Serum-free medium-treated cultures (Stu-
dent’s t-test, p < 0.05)
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6 h (Fig. 6). MsN and RECN treatment of PSV1 and
S180-NCAD cells induced cytoskeleton reorganisation
of cells: loss of stress fibres, and more filopodia-like
extensions were formed and cells were more elongated,
compared to cells treated with Serum-free medium.
Cytoskeleton reorganisation induced by sN-CAD was
counteracted by adding PD173074.
Discussion
We present here evidence that a hu HAV N-CAD10
peptide (LRAHAVDING) induces angiogenesis in
the CAM and in the rabbit cornea assay dose-
dependently. Several experiments have been pub-
lished with substratum bound N-cadherin peptides
containing HAV-sequence dimeric versions of the N-
CAD peptides promote neuronal cell survival and
neurite outgrowth, while cyclic peptides containing
the HAV-sequence of extracellular domain 1 induce
FGF-receptor-mediated apoptosis in endothelial cells
[36] and inhibit neurite outgrowth [37]. When
presented as soluble molecules, dimeric peptides
stimulate neurite outgrowth in a manner similar to
native N-cadherin [38, 39].
As a better approach of the physiological situation
we tested the complete ectodomain of N-cadherin (90-
kDa extracellular N-cadherin fragment, sN-CAD) in
two angiogenesis models in vivo, where sN-CAD
stimulated angiogenesis in both assays. Different pro-
teases have already been described which are able to
cleave N-cadherin extracellularly, like MMP [23] and
ADAM10 (protein with a disintegrin and a metallo-
protease domain) [40], giving rise to a 90-kDa sN-CAD
fragment. Other proteases like presenilin/c-secretase
[41] and caspase-3 [42] are able to cleave N-cadherin
intracellularly. In tumours sN-CAD can originate from
different cell types, like endothelial, fibroblast, cancer
cells,...because N-cadherin on the cell membrane can
be cleaved by multiple proteases present in the
Fig. 5 sN-CAD stimulates ERK phosphorylation a sN-CAD
induces ERK phosphorylation. PSV1 and S180-NCAD were
serum-starved and treated for 30 min with serum-free medium
(SFM), medium containing sN-CAD (MsN), RECN (5 lg/ml) or
FGF-2 (12.5 ng/ml) without or with PD173074 (PD). Equal
amounts of protein were loaded on SDS-PAGE and stained with
an antibody against phospho-ERK and with an antibody for total
ERK. Immunoblots from phospho-ERK and total ERK were
quantified with a Quantity-One software (Bio-Rad) and the
relative intensity is the value of p-ERK corrected for the amount
of total ERK present. This result is representative for at least
three independent experiments performed. b PSV1 cells,
knocked down with oligonucleotides against N-cadherin, the
FGF-receptor or a non-mammalian target, were serum starved
after 60 h and after 72 h treated with serum-free medium (SFM)
or RECN (5 lg/ml) during 30 min. Cells were lysed and equal
amounts of protein were loaded on SDS-PAGE. Western blot
was stained for N-cadherin, the FGF-receptor, phospho-ERK
and total ERK and tubulin. All imunoblots were quantified with
the Quantity-One software. This experiment was done twice and
gave the same result
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micro-environment We used plasmin, a serine prote-
ase, to cleave N-cadherin in its extracellular domain, in
order to release a 90-kDa sN-CAD in culture medium
of the cells.
To elucidate the possible working mechanism we
tested both the medium containing sN-CAD and the
dimeric recombinant N-cadherin/Fc chimera (termed
both as sN-CAD) in vitro, which consist of the extra-
cellular part of N-cadherin linked to the Fc fragment of
the human IgG1 antibody. N-cadherin is known as a
cell–cell adhesion molecule, but it is also a pro-migra-
tory factor, since transfection of epithelial cells with N-
cadherin induces the motile phenotype [43, 44]. The
domain implicated in migration was restricted to 69
amino acids in extracellular domain 4 [45]. Although
the role of N-cadherin in endothelial cells is not yet
completely clear, it is important for its interaction with
surrounding pericytes in the micro-environment [19].
Recent knock-down experiments of N-cadherin in
endothelial cells showed a role of N-cadherin during
vasculogenesis [20]. Furthermore, recombinant N-
cadherin/Fc chimera was shown to stimulate neurite
outgrowth in an FGF-receptor-dependent manner [46],
but nothing has been reported to date about its func-
tion in migration and invasion of endothelial cells. We
found that sN-CAD stimulates the migration of endo-
thelial cells and this event requires the presence of
N-cadherin on the acceptor cells, because silencing of
N-cadherin by siRNA in the endothelial cells strongly
reduced the sN-CAD pro-migratory effect and S180
(N-cadherin negative, parent) cells cannot be stimu-
lated by sN-CAD containing medium nor by re-
combinant N-cadherin. We observed no differences in
the cell–cell adhesion of endothelial cells when they
were treated with sN-CAD or HAV N-CAD10 peptide
(data not shown). So, the sN-CAD-stimulated migra-
tion is not due to alterations in cell–cell adhesion.
We also investigated the role of the FGF-receptor
in the pro-migratory effect of sN-CAD, because we
could demonstrate that N-cadherin co-immunopre-
cipitates with the FGF-receptor. It was shown in
literature that in neuronal cells N-cadherin interacts
directly with the FGF-receptor via the HAV-binding
region present in extracellular domain 4 of N-cadh-
erin [47], and by this prolongs the activation of the
FGF-receptor by stabilisation of the receptor on the
membrane [35]. In pancreatic tumour cells as well as
in neurons N-cadherin can trigger FGF-receptor sig-
nalling independently from FGF [48, 49]. Indeed we
were able to reduce sN-CAD-mediated migration of
endothelial cells in two ways. First, by using a spe-
cific inhibitor PD173074, which binds to the ATP
pocket of the FGF-receptor [27], and second by
knocking down the FGF-receptor by siRNA. FGF-
stimulated chemotaxis and/or chemokinesis in endo-
thelial cells requires the activation of the ERK
signalling pathway [11]. We confirmed that both sN-
CAD containing medium and recombinant N-cadh-
erin stimulated phosphorylation of ERK, and this
was abolished by addition of the FGF-receptor
inhibitor, PD173074. However, the stimulated phos-
phorylation of ERK induced by sN-CAD containing
medium could not be blocked by the FGF-receptor
inhibitor, presumably because of the presence of
other growth factors.
Cytoskeletal reorganisation is essential for migra-
tion of endothelial cells and therefore the formation of
new vessels. sN-CAD stimulates the loss of stress fibres
and the formation of filopodia and cells become elon-
gated. Again these effects are N-cadherin- and FGF-
receptor-dependent as evidenced by using siRNA in
endothelial cells and N-cadherin-deficient S180 cells. It
is noteworthy that sN-CAD stimulates the activation of
Cdc42 which usually held responsible for the formation
Fig. 6 sN-CAD induces
filopodia formation. PSV1
and S180-NCAD were
sparsely seeded on glass
coverslips and grown until
islands of cells were formed.
Cells were put on serum-free
medium (SFM) overnight and
treated with SFM, medium
containing sN-CAD (MsN),
RECN (5 lg/ml), RECN with
PD173074 or PD173074
(500 nM) alone for 6 h. Actin
filaments were visualised with
FITC-phalloidin. Scale bar,
50 lm
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of filopodia, and diminishes the activation of RhoA
(data not shown).
Comparable results were published with another
neural cell adhesion molecule, L1. Plasmin is respon-
sible for the posttranslational cleavage of L1 in fibro-
nectin domain 3 of the molecule with the release of a
150-kDa fragment in the medium [50], and ADAM10
can also cleave L1 extracellularly with the shedding of
a 200-kDa fragment. Both L1 extracellular fragments
can stimulate cell migration [51]. Furthermore, pro-
migratory effects were observed also with other soluble
cadherins, like sE-cadherin [22].
In ‘‘quiescent’’ endothelial cells N-cadherin is
responsible for the adhesion with other endothelial
cells and with stromal cells like pericytes (Fig. 7).
However in the micro-environment of tumours and in
inflammatory processes, numerous proteases activate
endothelial cells to form new blood vessels. We hy-
pothesise that sN-CAD plays an important role in this
process. Proteases cleave the extracellular fragment of
N-cadherin from stromal cells, endothelial cells or N-
cadherin-expressing tumour cells. sN-CAD will on its
turn interact with the N-cadherin/FGF-receptor com-
plex present on endothelial cells and stimulate the
migration of endothelial cells in an FGF-receptor-
dependent manner. sN-CAD activates the ERK path-
way, leading to upregulation of protease expression,
like plasmin and MMP, via the zinc-finger transcription
factor Ets-1 [52], which has indeed been shown to in-
duce angiogenesis [53]. By this an autocrine loop is
formed: newly expressed proteases on their turn are
responsible for the formation of sN-CAD which again
induces migration of the endothelial cells.
Our results indicate that sN-CAD stimulates
angiogenesis in vivo and migration of endothelial cells
in vitro through an N-cadherin/FGF-receptor complex.
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